Free interactive tool
You are FDA-eligible for a GLP-1 weight-loss prescription if your BMI is 30+ (or 27+ with a weight-related comorbidity like type 2 diabetes, hypertension, sleep apnea, or dyslipidemia). The decision tree below walks you through the official Wegovy, Zepbound, Ozempic, and Mounjaro criteria, screens for absolute contraindications, and tells you whether to pursue a prescription — or what to discuss with your prescriber first.
Step 1 of 8
13%
Pick the closest match. We branch the rest of the questions based on this answer.
Educational tool only. Not a clinical assessment. Your prescriber must confirm eligibility, order labs, and screen for personal contraindications before any prescription.
Wegovy/Zepbound require BMI ≥30 (or ≥27 with comorbidity). Ozempic/Mounjaro require a type 2 diabetes diagnosis. We branch the question flow so you only see the criteria that apply to you.
MTC / MEN 2 family history is an absolute contraindication on every GLP-1 label. Pregnancy and severe gastroparesis are also screening priorities — we flag any of these as hard stops.
Prior pancreatitis, type 1 diabetes, and severe kidney impairment require specialist evaluation before starting. The tool surfaces these as caveats rather than hard stops.
Self-injection comfort and budget realism. If oral-only is required, we surface Rybelsus. If self-pay budget is tight, we flag the typical $349–$650/month range before you commit.